Crossmark

Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer

Crossref DOI link: https://doi.org/10.1007/s11864-018-0521-5

Published Online: 2018-01-24

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vaishampayan, Ulka
License Information

Text and Data Mining valid from 2018-01-01
More Information

Article History

First Online: 24 January 2018

Compliance with Ethical Standards

:

: Ulka Vaishampayan has received research funding through grants from Exelixis, Pfizer, Novartis, Bristol-Myers Squibb, Genentech, Bayer, and Astellas, and has received compensation from Exelixis, Pfizer, Novartis, Bristol-Myers Squibb, Genentech, Bayer, Astellas, and Sanofifor service as a consultant.

: This article does not contain any studies with human or animal subjects performed by any of the authors.